



December 20, 2016

Novartis Pharma AG

CH-4002, Basel, Switzerland

Reference: EudraCT 2011-001884-39/ Novartis Protocol ID CBEZ235ZIC01

*A phase II study of orally administered BEZ235 monotherapy in patients with metastatic or unresectable malignant PEComa*

Trial CBEZ235ZIC01 was cancelled with no patient enrollment and as such, no results will be reported.